ZFAND5 Is an Independent Prognostic Biomarker of Perihilar Cholangiocarcinoma

Pei Liu, Yijia Wang, Lingling DuanFrontiers in Oncology 2022 · DOI

TL;DR

Researchers have identified the protein ZFAND5 as a potent, independent prognostic biomarker for perihilar cholangiocarcinoma (pCCA), a highly aggressive bile duct cancer. Patients with high ZFAND5 expression showed significantly shorter survival times (19.5 months vs. 31.2 months), suggesting this protein could be key to stratifying high-risk patients and developing targeted therapies.

What Problem Does This Paper Address?

Cholangiocarcinoma (CCA) is a devastating malignancy of the bile ducts with a notoriously poor prognosis. Among its subtypes, perihilar CCA (pCCA) is the most common, yet it remains the least studied in terms of molecular biomarkers. This is largely due to the anatomical complexity of the hepatic portal, which makes obtaining high-quality tissue specimens difficult.

The protein ZFAND5 (also known as ZNF216) is known to interact with the cell's "trash disposal" system—the ubiquitin-proteasome pathway—to promote protein degradation. While its role in muscle atrophy is well-documented, its function in cancer has been controversial, with some studies suggesting it prevents tumor growth and others suggesting it promotes it. This paper seeks to clarify ZFAND5's role specifically within the context of pCCA.

Methods

The researchers employed a combination of histological and molecular techniques to evaluate a patient cohort:

  • Tissue Microarray (TMA) & IHC: They constructed TMAs from 72 pCCA patients and used Immunohistochemistry (IHC) to score ZFAND5 protein levels.
  • qRT-PCR: To validate protein findings at the genetic level, they measured ZFAND5 mRNA in a separate prospective cohort of 10 patients.
  • Statistical Stratification: They used Receiver Operating Characteristic (ROC) curves to establish a rigorous "cut-off" score (3.5) to divide patients into ZFAND5-high and ZFAND5-low groups.
  • Survival Analysis: The team used Kaplan-Meier curves and Cox-regression models to determine if ZFAND5 expression was an "independent" predictor—meaning its prognostic value held up even when accounting for age, sex, tumor size, and cancer stage.

Datasets

  • Retrospective Cohort: 72 patients (selected from an initial 122) who underwent radical surgery for pCCA between 2017 and 2021 at Qilu Hospital and the Central Hospital of Shandong First Medical University.
  • Prospective Cohort: 10 consecutive patients used specifically for mRNA quantification via qRT-PCR.
  • Control Tissues: The study used paired healthy liver tissues, intrahepatic bile duct tissues, and common bile duct (CBD) tissues as benchmarks for "normal" expression.

Key Insights and Ideas

  • Upregulation in Cancer: ZFAND5 expression was significantly higher in pCCA tumors than in healthy bile ducts. Interestingly, it was lower in tumors than in healthy liver tissue, highlighting that its role is highly tissue-specific.
  • The "Trash Disposal" Advantage: The authors speculate that ZFAND5 might help cancer cells survive the metabolic stress of rapid growth by enhancing autophagy (self-eating) or proteasome activity, allowing the cells to recycle nutrients and clear damaged proteins more efficiently.
  • Independent Risk Factor: One of the most critical findings was that ZFAND5-high status was an independent predictor of poor outcomes. Even if two patients had the same tumor size and clinical stage, the one with high ZFAND5 expression faced a much higher risk of death.
  • A Potential Immune Link: The paper notes that ZFAND5 can be induced by inflammatory cytokines (like TNFα) and may inhibit NF-κB signaling, suggesting a possible role in how the tumor interacts with the immune system.

Key Results

  • Survival Gap: Patients in the ZFAND5-low group had an average survival of 31.2 months, while the ZFAND5-high group dropped to 19.5 months.
  • 5-Year Survival: The 5-year survival rate for the ZFAND5-low group was 31.9%, whereas 0% of the ZFAND5-high group survived to the 5-year mark.
  • Hazard Ratio: Multivariate analysis revealed that ZFAND5-high patients were 4.33 times more likely to suffer pCCA-related death than ZFAND5-low patients (HR=4.33, p < 0.001).
  • Prevalence: 55.6% of the pCCA cohort were classified as ZFAND5-high.

Limitations and Future Work

  • Sample Size: While 72 patients is a respectable cohort for this specific subtype, larger multi-center studies are needed to validate these findings for clinical use.
  • Mechanistic Mystery: The study establishes a strong correlation between ZFAND5 and poor prognosis, but the exact biochemical "how" remains speculative. The authors call for further research into whether ZFAND5 functions as an E3 ligase in pCCA.
  • Therapeutic Potential: Future work should investigate whether ZFAND5 could be a therapeutic target. If ZFAND5 helps cancer cells survive stress, inhibiting it might sensitize tumors to existing treatments like chemotherapy.

Summary updated

Abstract

ZFAND5 expression was up-regulated in pCCAs compared with the CBDs. We identified ZFAND5 as an independent biomarker of pCCA, which could provide more evidence for the molecular classification of pCCA, and help stratify the high-risk patients based on the molecular features.
BibTeX
@inproceedings{liu2022zfand,
  author = {Pei Liu and Yijia Wang and Lingling Duan},
  title = {{ZFAND5 Is an Independent Prognostic Biomarker of Perihilar Cholangiocarcinoma}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.955670},
}
Figure